- Home
- BOLD vs RDI Comparison
BOLD vs RDI Comparison
Compare BOLD & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | RDI |
|---|---|---|
| Founded | 2018 | 1937 |
| Country | United States | United States |
| Employees | N/A | 2025 |
| Industry | | Movies/Entertainment |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 23.6M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | BOLD | RDI |
|---|---|---|
| Price | $1.13 | $1.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 57.3K | 19.1K |
| Earning Date | 06-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $0.94 |
| 52 Week High | $1.78 | $1.65 |
Technical Indicators
Market Signals| Indicator | BOLD | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 50.27 |
| Support Level | $1.10 | $0.98 |
| Resistance Level | $1.19 | $1.16 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 37.50 | 63.03 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.